Drug Therapy of Depression

36

description

Depression

Transcript of Drug Therapy of Depression

Page 1: Drug Therapy of Depression
Page 2: Drug Therapy of Depression

• At the end of the lecture, students must be able to,

– Understand and explain the monoamine theory of

depression.

– Understand on the types of depression from the aspect of

pharmacological treatment.

– Classify the drugs for depression (unipolar)

– Describe the pharmacology of each drug (MOA, PA, uses,

adverse effects, drug interactions)

– Describe the drug therapy of bipolar disorder.

Page 3: Drug Therapy of Depression

• What is depression?

• Clinical features, types, theories and pathophysiology

of depression.

• Classification of antidepressant drugs

• Pharmacology of drugs

• Drug therapy of bipolar disorder

Page 4: Drug Therapy of Depression

• Depression is the most common of the affective disorders (disorder of mood).

• may range from a very mild condition, to severe (psychotic) depression accompanied by hallucinations and delusions.

• Worldwide, depression is a major cause of disability and premature death.

• In addition to the significant suicide risk, depressed individuals are more likely to die from other causes, such as heart disease or cancer.

• often associated with other psychiatric conditions including anxiety, eating disorders and drug addiction

Page 5: Drug Therapy of Depression

• Emotional symptoms

– low mood, excessive rumination of negative thought, misery, apathy and

pessimism

– low self-esteem: feelings of guilt, inadequacy and ugliness

– indecisiveness, loss of motivation

– loss of reward.

• Biological symptoms include:

– retardation of thought and action

– loss of libido

– sleep disturbance and loss of appetite.

Page 6: Drug Therapy of Depression

• Two distinct types

– Unipolar depression, in which the mood changes are

always in the same direction,

– Bipolar affective disorder, in which depression alternates

with mania.

Page 7: Drug Therapy of Depression

Bipolar depression

• less common

• oscillating depression and mania over a period of a few weeks.

• strong hereditary tendency

• 75% --- non-familial, (Neurotic)

• clearly associated with stressful life events,

• accompanied by symptoms of anxiety and agitation;

• this type is sometimes termed reactive depression.

• 25% ----- (endogenous depression) (psychotic)

• familial pattern,

• unrelated to obvious external stresses

Unipolar depression

Page 8: Drug Therapy of Depression

• main biochemical theory of depression - monoamine hypothesis,

• first proposed in 1965,

• which states that depression is caused by a functional deficit of the

monoamine transmitters, noradrenaline and 5-hydroxytryptamine (5-

HT) at certain sites in the brain,

• while mania results from a functional excess

Page 9: Drug Therapy of Depression
Page 10: Drug Therapy of Depression

A. Acute anxiety with depression:

e.g. benzodiazepines (Separate Lecture)

– mild, neurotic depression, esp. with anxiety.

– Short-term for acute onset.

– not effective for long-term treatment of psychotic

depression.

B. Antidepressants:

• for psychotic depression, severe neurotic depression; long-

term treatment.

Page 11: Drug Therapy of Depression

1. Monoamine uptake inhibitors

1. tricyclic antidepressants,

2. selective serotonin reuptake inhibitors,

3. newer inhibitors of noradrenaline and 5-HT reuptake

2. Monoamine receptor antagonists

3. Monoamine oxidase (MAO) inhibitors

Page 12: Drug Therapy of Depression
Page 13: Drug Therapy of Depression

• inhibit active uptake of biogenic amines noradrenaline and 5-HT into their

respective neurons,

• increasing their concentration in the synaptic cleft in the CNS and

periphery.

• Inhibition of NA and 5-HT uptake is associated with antidepressant action

• antidepressant action develops after weeks

Page 14: Drug Therapy of Depression

Pharmacological actions:

CNS:

– mood elevation of depressed patients (Use);

– may extend to excitement, hypomania, mania with sufficient dose; agitation,seizures

(Unt)

– no mood elevation or euphoria, but causes anxiety in normal persons.

– lowers seizure threshold, convulsions in overdose (Unt)

– respiratory depression with overdose (Unt)

ANS:

– anticholinergic action atropine-like effects (Unt)

– potentiates exogenous & endogenous noradrenaline, sympathomimetics (Unt)

CVS:

– orthostatic hypotension, sinus tachycardia; arrhythmias and cardiac conduction defect

with overdose (Unt)

Page 15: Drug Therapy of Depression

may be classified into those with:

(a) Marked sedation: suitable for anxious and agitated patients.***

- amitriptyline

- trimepramine

- doxepin

(b) Less sedation: suitable for withdrawn and apathetic patient*****

- imipramine - desipramine

- nortriptyline

Page 16: Drug Therapy of Depression

• MOA

– SERT mediates the reuptake of

serotonin into the presynaptic

terminal; neuronal uptake is

the primary process by which

neurotransmission via 5-HT is

terminated.

– SSRI blocks reuptake and

results in enhanced and

prolonged serotonergic

neurotransmission.

Page 17: Drug Therapy of Depression

• most commonly prescribed group of antidepressants

• Acute toxicity (especially cardiotoxicity) is less than that of MAOIs or TCAs, so

overdose risk is reduced.

• SSRIs are less sedating and have fewer antimuscarinic side effects than the older

TCAs.

• No food reactions,

• but dangerous 'serotonin reaction' (hyperthermia, muscle rigidity, cardiovascular

collapse) can occur if given with MAOIs.

• overall antidepressant efficacy similar to TCA, less efficacious in more severe

depression

• in general, SSRIs DO NOT: **** cause weight gain

Page 18: Drug Therapy of Depression

Disadvantages:

• Mild side-effects: nervousness, restlessness, insomnia, anorexia, headache, diarrhoea

• Impair performance of skilled tasks, e.g. driving;

• sexual dysfunctions

• May produce withdrawal symptoms needs tailing off

- Indication : better tolerated and safer in overdose than other classes,

should be considered first-line drugs for treating depression.

Page 19: Drug Therapy of Depression

in general, SSRIs DO NOT: ****

- produce anticholinergic side-effects

- cause postural hypotension, or inhibit cardiac conduction

- precipitate seizures

- interfere with cognitive and psychomotor functions, or cause

sedation

- cause weight gain; food and drug interactions

Page 20: Drug Therapy of Depression

= Non-selective monoamine uptake inhibitors

= serotonin/noradrenaline reuptake inhibitors, or 'SNRIs‘

• Eg. venlafaxine, desvenlafaxine

•MOA & status

•Generally similar to tricyclic antidepressants, fewer side effects.

•Less risk of cardiac effects, so safer in overdose than tricyclic

antidepressants.

•Can be used to treat other disorders: eg. anxiety disorder, neurpathic pain

Page 21: Drug Therapy of Depression
Page 22: Drug Therapy of Depression

• Mirtazapine

– Blocks α2 adrenoreceptors and 5-HT2C receptors,

– Block of α2 adrenoceptors will not only increase

noradrenaline release but will also enhance 5-HT release

• Trazodone

– 5-HT reuptake inhibition.

Page 23: Drug Therapy of Depression

• What are MAOs?

enzymes involved in deamination (degradation) of monoamines which include NA and 5-HT

• Two sub-types: – MAO-A, preferentially deaminates 5-HT and NA

– MAO-B, preferentially deaminates phenylethylamine and dopamine.

• Types of MAOI

1. Non selective MAOI

2. Selective MAOI

Page 24: Drug Therapy of Depression
Page 25: Drug Therapy of Depression

Nonselective MAOIs

• inactivate the enzymes irreversibly

• mood elevation in both normal and depressed patient

• effects last 2-3 weeks after discontinuation

Selective MAOIs: Meclobemide

• inhibits MAO-A selectively and reversibly

• effective antidepressant, except in severe cases

• lacks anticholinergic, sedative, psychomotor and cardiaovascular adverse effects of

typical TCAs

Status:

• well tolerated alternative to TCAs in mild to moderate depression;

• especially suitable for elderly patients and those with heart disease.

Page 26: Drug Therapy of Depression

Status:

• much less frequently used, because of

(i) Interactions:

- “cheese reaction” with food containing tyramine, dopamine etc., - cheese, beer, wines,

pickled meat and fish, yeast extract hypertensive crisis

- with TCAs severe toxicity resembling atropine poisoning

- with many others including: (indirect sympathomimetic drugs)

cold & cough remedies, antiparkinsonian drugs, pethidine, reserpine, guanethidine etc.

synergistic, adverse interactions

(ii) Untoward effects (adverse reactions),

- which include: CNS stimulation, anticholinergic effects, lowered convulsive

threshold, weight gain, and hepatotoxicity.

** overall antidepressant efficacy similar to TCA, less efficacious in more severe depression

Page 27: Drug Therapy of Depression
Page 28: Drug Therapy of Depression

• Mild depression - non-drug measures, antidepressant drugs – used - if

the response is poor.

• The use of antidepressant drugs is advisable in the treatment of

moderate to severe depression.

• Different classes of antidepressant drugs have similar efficacy but

different side effects.

• Choice of drug is based on individual aspects including concomitant

disease (TCAs in particular have several indications) and treatment

(MAOIs and TCAs cause important interactions), suicide risk and

previous response to treatment.

Page 29: Drug Therapy of Depression

• Other things being equal, an SSRI is preferred as these are usually better

tolerated and are less dangerous in overdose.

• Antidepressant drugs take several weeks before taking effect, so decisions

on dose increment or switching to another class should not be made

precipitately.

• An effective regimen should be continued for at least 2 years.

• In urgent situations, specialist consideration - possible use of

electroconvulsive therapy.

• Anxiolytic (e.g. benzodiazepine), or antipsychotic drugs are useful adjuncts

in some patients.

Page 30: Drug Therapy of Depression

• Important points for drug therapy:

– reviewed every 1 – 2 weeks at start of therapy

– continued for at least 4 weeks (6 weeks in elderly) before

contemplating switch

– following remission, continue same dose for at least 6 months

(12 months for elderly, 2 years for recurrent depression)

– withdrawal symptoms if stopped suddenly after 8 weeks or more, (physical

dependence); needs tailing off (4 weeks or longer)

– at least 2 weeks gap in-between, when switching drugs

Page 31: Drug Therapy of Depression

• neuropathic pain (e.g. amytriptyline, nortryptyline)

• anxiety disorders (e.g. SSRIs, venlafaxine, duloxetine)

• fibromyalgia (e.g. duloxetine, venlafaxine, SSRIs, TCAs)

• bipolar depression (e.g. fluoxetine)

• smoking cessation (e.g. buproprion)

• attention-deficit hyperactivity disorder.

Page 32: Drug Therapy of Depression

Drug used – lithium (mood stabilizer)

– several antiepileptic drugs, e.g. carbamazepine, valproate, lamotrogine

– some atypical antipsychotic drugs, e.g. olanzapine, risperidone.

MOA – Lithium is a monovalent cation

– can mimic the role of Na+ in excitable tissues,

– able to permeate the voltage-gated Na+ channels that are responsible for action potential generation

– not pumped out by the Na+-K+-ATPase, and therefore tends to accumulate inside excitable cells, leading to a partial loss of intracellular K+, and depolarisation of the cell

Page 33: Drug Therapy of Depression

• Narrow Therapeutic Index: requires frequent (or regular) monitoring of serum

drug levels. (clinically effective at a plasma concentration of 0.5-1 mmol/l, and above 1.5

mmol/L)

• Na+ depletion reduces the rate of excretion by increasing the reabsorption of lithium by the

proximal tubule, and thus increases the likelihood of toxicity. -- ***** low salt diet

increases serum drug level of lithium.*****

The main toxic effects • nausea, vomiting and diarrhoea, tremor

• renal effects:

polyuria --- resulting from inhibition of the action of antidiuretic hormone.

(nephrogenic Diabetes insipidus)

• thyroid enlargement, sometimes associated with hypothyroidism

• weight gain

• hair loss.

Page 34: Drug Therapy of Depression

• Lithium – classical drug. – used in prophylaxis and treatment of mania, and in the prophylaxis of bipolar disorder. – Points for lithium – there is a narrow therapeutic window and long duration of action – acute toxic effects include cerebellar effects, nephrogenic diabetes insipidus and renal

failure – dose must be adjusted according to the plasma concentration – elimination is via the kidney and is reduced by proximal tubular reabsorption. – Diuretics increase the activity of the reabsorptive mechanism and hence can precipitate

lithium toxicity – thyroid disorders occur during chronic use.

• Carbamazepine valproate and lamotrogine (sodium channel blockers with antiepileptic actions) are used for: – the prophylaxis and treatment of manic episodes in patients with bipolar disorder – the treatment of bipolar depression.

• Olanzapine, risperidone (atypical antipsychotic drugs) are used to treat mania.

Page 35: Drug Therapy of Depression

1. Monoamine uptake inhibitors

1. tricyclic antidepressants (imipramine, desipramine, amitriptyline)

2. selective serotonin reuptake inhibitors (fluoxetine, fluvoxamine)

3. newer inhibitors of noradrenaline and 5-HT reuptake (venlafaxine ,

desvenlafaxine, duloxetine)

4. NA reuptake inhibitor (bupropion)

2. Monoamine receptor antagonists (mirtazapine, trazodone)

3. Monoamine oxidase (MAO) inhibitors

phenelzine - non-selective with respect to the MAO-A and -B

subtypes.

MAO-A-selective inhibitors (e.g. moclobemide).

Page 36: Drug Therapy of Depression

References

• Brunton, L. Chabner, B. Knollman, B. Goodman & Gilman’s

Pharmacological Basis of Therapeutics. 12th Edition. United States:

The McGraw-Hill Companies, Inc.

• Rang, HP, Dale, MM, Ritter, JM, Flower, RJ, Henderson, G

(2012). Rang and Dale's Pharmacology. 7th ed. London: Elsevier

Churchill Livingstone